Clinical Trials Logo
  1. Home
  2. Chronic Myelogenous Leukemia
  3. NCT00413270

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Chronic Myelogenous Leukemia Clinical Trial

Official title:
A Canadian Open-label, Multicenter, Expanded Access Study of Oral Nilotinib in Adult Patients With Imatinib-resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase

Clinical Trial Summary

This study will evaluate the safety of nilotinib in adult patients with imatinib-resistant or -intolerant CML-blast crisis, CML-accelerated phase or CML-chronic phase when treated with nilotinib. Patients will be provided access to nilotinib until the drug is available on the market.

Clinical Trial Description

n/a

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00413270
Study type Expanded Access
Source Novartis
Contact
Status No longer available
Phase Phase 3
Start date December 2006
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT02592447 - Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention N/A
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Terminated NCT01397734 - Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Phase 1
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Withdrawn NCT01011998 - A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) Phase 2
Completed NCT00378534 - Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants Phase 2
Completed NCT00098033 - Investigation of Clofarabine in Acute Leukemias Phase 2
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Completed NCT02581007 - Reduced Intensity Conditioning Transplant Using Haploidentical Donors Phase 2
Terminated NCT03547154 - Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) Phase 2/Phase 3
Terminated NCT02709083 - Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia Phase 2
Terminated NCT02145039 - Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases N/A
Terminated NCT02146846 - Population Pharmacokinetics of Imatinib in CML Patients in Iran N/A
Active, not recruiting NCT01036009 - A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies Phase 2
Completed NCT00990587 - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Phase 1
Terminated NCT00594308 - In-Vivo Activated T-Cell Depletion to Prevent GVHD N/A
Terminated NCT00500006 - A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) Phase 1
Completed NCT00493181 - Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients Phase 2